CC
GLUE icon

Corton Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

Corton Capital’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29,348
Closed -$136K – 368
2025
Q1 		$136K Sell
29,348
-3,018
-9% -$18.5K 0.45% 99
2024
Q4 		$225K Buy
+32,366
New +$243K 0.13% 223
2023
Q4 		– Sell
-14,460
Closed -$69.3K – 608
2023
Q3 		$69.3K Buy
+14,460
New +$93.1K 0.04% 403

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Corton Capital's GLUE Position: Q2 2025 in Review

Corton Capital sold out of Monte Rosa Therapeutics (GLUE) in Q2 2025, closing a stake of 29,348 shares — an estimated $136K sold.

Corton Capital first reported a position in GLUE in Q3 2023 and held it in 3 quarters. The position peaked at $225K in Q4 2024. 116 funds tracked by Wall St. Rank hold GLUE as of Q2 2025.

  • Corton Capital reported no remaining Monte Rosa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corton Capital sold 29,348 Monte Rosa Therapeutics shares in Q2 2025, an estimated $136K.
  • Corton Capital first reported a position in Monte Rosa Therapeutics in Q3 2023 and held it in 3 quarters.
  • Corton Capital's Monte Rosa Therapeutics position peaked at $225K in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2025.

Based on Corton Capital's 13F filing for Q2 2025, filed 5 Aug 2025.